CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Protara Therapeutics, Inc. - TARA CFD

1.58
3.27%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.09
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Protara Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.53
Open* 1.65
1-Year Change* -45.54%
Day's Range* 1.58 - 1.67
52 wk Range 1.12-4.18
Average Volume (10 days) 45.15K
Average Volume (3 months) 618.99K
Market Cap 12.96M
P/E Ratio -100.00K
Shares Outstanding 11.36M
Revenue N/A
EPS -6.13
Dividend (Yield %) N/A
Beta 1.07
Next Earnings Date Mar 6, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 8, 2023 1.53 0.16 11.68% 1.37 1.59 1.37
Dec 7, 2023 1.35 -0.05 -3.57% 1.40 1.41 1.35
Dec 6, 2023 1.39 0.03 2.21% 1.36 1.39 1.35
Dec 5, 2023 1.36 -0.03 -2.16% 1.39 1.43 1.32
Dec 4, 2023 1.37 -0.04 -2.84% 1.41 1.44 1.34
Dec 1, 2023 1.40 0.02 1.45% 1.38 1.43 1.37
Nov 30, 2023 1.38 0.02 1.47% 1.36 1.49 1.24
Nov 29, 2023 1.47 0.06 4.26% 1.41 1.60 1.41
Nov 28, 2023 1.39 0.11 8.59% 1.28 1.39 1.28
Nov 27, 2023 1.31 0.14 11.97% 1.17 1.31 1.17
Nov 24, 2023 1.15 -0.01 -0.86% 1.16 1.18 1.13
Nov 22, 2023 1.08 -0.04 -3.57% 1.12 1.13 1.04
Nov 21, 2023 1.12 -0.01 -0.88% 1.13 1.17 1.12
Nov 20, 2023 1.12 0.01 0.90% 1.11 1.16 1.11
Nov 17, 2023 1.12 -0.01 -0.88% 1.13 1.18 1.10
Nov 16, 2023 1.12 -0.04 -3.45% 1.16 1.21 1.10
Nov 15, 2023 1.18 0.02 1.72% 1.16 1.22 1.14
Nov 14, 2023 1.17 0.05 4.46% 1.12 1.19 1.12
Nov 13, 2023 1.13 0.00 0.00% 1.13 1.14 1.11
Nov 10, 2023 1.14 -0.05 -4.20% 1.19 1.19 1.06

Protara Therapeutics, Inc. Events

Time (UTC) Country Event
Wednesday, March 6, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Protara Therapeutics Inc Earnings Release
Q4 2023 Protara Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Revenue 0 0
Total Operating Expense 67.062 47.489 34.444 15.254 21.372
Selling/General/Admin. Expenses, Total 20.627 26.401 22.462 8.816 9.524
Research & Development 16.671 21.088 11.982 6.438 11.848
Operating Income -67.062 -47.489 -34.444 -15.254 -21.372
Interest Income (Expense), Net Non-Operating 1.11 0.237 0.466 0.262 0.436
Other, Net 0 0.207
Net Income Before Taxes -65.952 -47.252 -33.978 -14.992 -20.729
Net Income After Taxes -65.952 -47.252 -33.978 -14.992 -20.729
Net Income Before Extra. Items -65.952 -47.252 -33.978 -14.992 -20.729
Net Income -65.952 -47.252 -33.978 -14.992 -20.729
Total Adjustments to Net Income 0
Income Available to Common Excl. Extra. Items -65.952 -47.252 -33.978 -14.992 -20.729
Income Available to Common Incl. Extra. Items -65.952 -47.252 -33.978 -14.992 -20.729
Diluted Net Income -65.952 -47.252 -33.978 -14.992 -20.729
Diluted Weighted Average Shares 11.2596 11.2326 7.23391 0.49728 0.45256
Diluted EPS Excluding Extraordinary Items -5.85739 -4.20669 -4.69704 -30.1483 -45.8044
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -3.2359 -4.20669 -4.69704 -30.1483 -45.8044
Total Extraordinary Items
Depreciation / Amortization 0.247
Unusual Expense (Income) 29.517
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 12.14 9.732 39.509 7.974 8.705
Selling/General/Admin. Expenses, Total 4.893 4.589 5.003 4.508 5.621
Research & Development 7.247 5.143 4.989 3.466 3.084
Operating Income -12.14 -9.732 -39.509 -7.974 -8.705
Interest Income (Expense), Net Non-Operating 0.846 0.687 0.542 0.283 0.166
Net Income Before Taxes -11.294 -9.045 -38.967 -7.691 -8.539
Net Income After Taxes -11.294 -9.045 -38.967 -7.691 -8.539
Net Income Before Extra. Items -11.294 -9.045 -38.967 -7.691 -8.539
Net Income -11.294 -9.045 -38.967 -7.691 -8.539
Income Available to Common Excl. Extra. Items -11.294 -9.045 -38.967 -7.691 -8.539
Income Available to Common Incl. Extra. Items -11.294 -9.045 -38.967 -7.691 -8.539
Diluted Net Income -11.294 -9.045 -38.967 -7.691 -8.539
Diluted Weighted Average Shares 11.3078 11.3039 11.2675 11.2655 11.2552
Diluted EPS Excluding Extraordinary Items -0.99878 -0.80017 -3.45836 -0.68271 -0.75867
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.99878 -0.80017 -0.8387 -0.68271 -0.75867
Unusual Expense (Income) 29.517
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 86.146 93.112 169.435 6.975 23.236
Cash and Short Term Investments 84.37 91.229 168.598 6.181 21.867
Cash & Equivalents 24.127 35.724 168.598 6.181 19.371
Short Term Investments 60.243 55.505 0 2.496
Prepaid Expenses 1.163 1.883 0.787 0.744 1.369
Total Assets 113.29 172.596 203.157 6.975 23.521
Property/Plant/Equipment, Total - Net 7.869 8.89 2.3 0 0.263
Property/Plant/Equipment, Total - Gross 8.352 9.126 2.419 0 1.09
Accumulated Depreciation, Total -0.483 -0.236 -0.119 0 -0.827
Other Long Term Assets, Total 1.389 1.61 1.905 0 0.022
Total Current Liabilities 5.74 4.298 2.915 0.583 3.078
Accounts Payable 1.586 0.954 0.914 0.263 0.441
Accrued Expenses 4.154 3.344 2.001 0.32 2.637
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total
Total Liabilities 11.207 10.682 3.914 0.583 3.078
Total Long Term Debt 0 0 0 0 0
Total Equity 102.083 161.914 199.243 6.392 20.443
Common Stock 0.011 0.011 0.011 0 0.019
Additional Paid-In Capital 262.724 256.126 245.992 213.388 209.366
Retained Earnings (Accumulated Deficit) -159.964 -94.012 -46.76 -225.462 -210.47
Other Equity, Total -0.688 -0.211 0.003 0.005
Total Liabilities & Shareholders’ Equity 113.29 172.596 203.157 6.975 23.521
Total Common Shares Outstanding 11.2674 11.2357 11.2118 0.55763 0.48109
Redeemable Preferred Stock 18.463 21.523
Other Current Assets, Total 0.127 0 0.05 0.05
Preferred Stock - Non Redeemable, Net 0
Total Preferred Shares Outstanding 0.00803 0.00803 0.00803 0.01895
Goodwill, Net 0 29.517 29.517
Other Liabilities, Total 5.467 6.384 0.999
Long Term Investments 17.886 39.467
Total Receivables, Net 0.486
Accounts Receivable - Trade, Net 0.486
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 77.813 84.265 94.616 86.146 98.667
Cash and Short Term Investments 74.034 80.36 86.61 84.37 96.317
Cash & Equivalents 33.768 33.978 21.035 24.127 47.498
Short Term Investments 40.266 46.382 65.575 60.243 48.819
Prepaid Expenses 3.498 3.56 7.388 1.163 1.97
Other Current Assets, Total 0.002 0.001 0.127 0.127 0
Total Assets 88.467 95.141 106.405 113.29 148.591
Property/Plant/Equipment, Total - Net 6.968 7.25 7.565 7.869 8.168
Goodwill, Net 0 29.517
Long Term Investments 0 0 2.893 17.886 10.76
Other Long Term Assets, Total 3.686 3.626 1.331 1.389 1.479
Total Current Liabilities 6.775 4.932 6.41 5.74 3.711
Accounts Payable 2.504 1.852 4.081 1.586 0.456
Accrued Expenses 4.271 3.08 2.329 4.154 3.255
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 11.511 9.916 11.637 11.207 9.413
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 4.736 4.984 5.227 5.467 5.702
Total Equity 76.956 85.225 94.768 102.083 139.178
Common Stock 0.011 0.011 0.011 0.011 0.011
Additional Paid-In Capital 267.273 265.853 264.235 262.724 261.294
Retained Earnings (Accumulated Deficit) -190.163 -180.303 -169.009 -159.964 -120.997
Other Equity, Total -0.165 -0.336 -0.469 -0.688 -1.13
Total Liabilities & Shareholders’ Equity 88.467 95.141 106.405 113.29 148.591
Total Common Shares Outstanding 11.3649 11.308 11.3068 11.2674 11.2674
Total Preferred Shares Outstanding 0.00799 0.00803 0.00803 0.00803 0.00803
Total Receivables, Net 0.279 0.344 0.491 0.486 0.38
Accounts Receivable - Trade, Net 0.279 0.344 0.491 0.486 0.38
Preferred Stock - Non Redeemable, Net 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -65.952 -47.252 -33.978 -14.992 -20.729
Cash From Operating Activities -26.457 -34.502 -23.407 -15.646 -23.233
Cash From Operating Activities 0.248 0.117 0.103 0.279 0.115
Non-Cash Items 38.708 13.149 9.839 0.956 3.402
Changes in Working Capital 0.539 -0.516 0.629 -1.889 -6.021
Cash From Investing Activities 14.95 -98.194 2.835 2.484 18.427
Capital Expenditures -0.12 -0.596 -0.884 -0.016 -0.119
Other Investing Cash Flow Items, Total 15.07 -97.598 3.719 2.5 18.546
Cash From Financing Activities -0.09 -0.228 189.401 0 2.985
Financing Cash Flow Items
Issuance (Retirement) of Stock, Net -0.09 -0.228 191.07 0 2.985
Foreign Exchange Effects 0 0.022
Net Change in Cash -11.597 -132.924 168.829 -13.162 -1.799
Cash Interest Paid 0 0 0.034
Issuance (Retirement) of Debt, Net 0 -1.669
Cash Taxes Paid 0 0
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -9.045 -65.952 -26.985 -19.294 -10.755
Cash From Operating Activities -12.888 -26.457 -21.431 -16.084 -10.961
Cash From Operating Activities 0.077 0.248 0.173 0.109 0.056
Non-Cash Items 1.845 38.708 7.311 5.26 2.289
Cash Interest Paid 0
Changes in Working Capital -5.765 0.539 -1.93 -2.159 -2.551
Cash From Investing Activities 9.86 14.95 33.295 14.247 0.745
Capital Expenditures -0.006 -0.12 -0.114 -0.031 -0.011
Other Investing Cash Flow Items, Total 9.866 15.07 33.409 14.278 0.756
Cash From Financing Activities -0.064 -0.09 -0.09 -0.072 -0.072
Issuance (Retirement) of Stock, Net -0.064 -0.09 -0.09 -0.072 -0.072
Net Change in Cash -3.092 -11.597 11.774 -1.909 -10.288
Issuance (Retirement) of Debt, Net
Cash Taxes Paid 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Opaleye Management Inc. Hedge Fund 23.7671 2692594 0 2023-06-30 MED
Shefferman (Jesse M) Individual Investor 7.1714 812454 -9310 2023-06-27 LOW
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 6.8195 772584 -20974 2023-06-30 LOW
Marshall (Randall S) Individual Investor 5.169 585600 0 2023-04-11 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.7745 427612 0 2023-06-30 LOW
Medical Strategy GmbH Investment Advisor 2.2512 255044 -41727 2023-05-31 MED
Boxer Capital, L.L.C. Hedge Fund 1.8468 209227 0 2023-06-30 LOW
Baker Bros. Advisors LP Hedge Fund 1.7625 199671 0 2023-06-30 LOW
Beshar (Luke M) Individual Investor 1.7477 198000 0 2023-04-11 LOW
Ikarian Capital LLC Hedge Fund 1.6653 188664 0 2023-06-30 HIGH
Privium Fund Management (UK) Ltd Investment Advisor 1.0568 119730 0 2023-06-30 HIGH
Renaissance Technologies LLC Hedge Fund 0.7379 83600 24694 2023-06-30 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.7363 83420 0 2023-06-30 LOW
Two Sigma Investments, LP Hedge Fund 0.5831 66063 -1300 2023-06-30 HIGH
Bridgeway Capital Management, LLC Investment Advisor 0.5649 64000 0 2023-06-30 MED
Zummo (Jacqueline) Individual Investor 0.4484 50799 -3824 2023-04-11 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.2922 33101 -854 2023-06-30 LOW
Garceau (Roger J) Individual Investor 0.2913 33000 0 2023-04-11 LOW
Levy (Richard S) Individual Investor 0.2736 31000 0 2023-04-11 LOW
Sargen (Gregory P) Individual Investor 0.2736 31000 0 2023-04-11 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Protara Therapeutics, Inc. Company profile

About Protara Therapeutics Inc

Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying therapies for the treatment of cancer and rare diseases. The Company's pipeline includes TARA-002, IV Choline Chloride and Vonapanitase. The Company's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is intravenous (IV) substrate replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD). Vonapanitase is a recombinant human elastase that are developing for the improvement of vascular access outcomes in patients with chronic kidney disease.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Protara Therapeutics Inc revenues was not reported. Net loss increased 39% to $47.3M. Higher net loss reflects Research and development - other increase of 75% to $19.7M (expense), General and administrative - other increase of 30% to $17.4M (expense), Stock-based Compensation in Research and increase of 90% to $1.4M (expense).

Industry: Bio Therapeutic Drugs

345 Park Avenue South
3rd Floor
NEW YORK
NEW YORK 10010
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

XRP/USD

0.63 Price
-6.480% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

41,828.95 Price
-4.510% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

1,982.69 Price
-1.080% 1D Chg, %
Long position overnight fee -0.0199%
Short position overnight fee 0.0117%
Overnight fee time 22:00 (UTC)
Spread 0.50

US100

16,162.80 Price
+0.670% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading